Trials / Completed
CompletedNCT00385008
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combination Product (sumatriptan succinate / naproxen sodium) | sumatriptan/naproxen sodium |
| DRUG | RELPAX(eletriptan) 40mg Tablet | eletriptan tablets |
Timeline
- Start date
- 2006-09-13
- Primary completion
- 2006-11-24
- Completion
- 2006-11-24
- First posted
- 2006-10-06
- Last updated
- 2018-02-12
- Results posted
- 2018-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00385008. Inclusion in this directory is not an endorsement.